Hi All,
So great to be back here & what a wonderful week for us in retrospect! Oversubscription to shortfall placement & now we are seeing some serious turn over (well for DXB) & rise in SP.
We are well funded for our FDA approved orphan status 2b trial for FSGS & beyond. I do also think there will be no issue with our DM trial being on track with a partner or Pharma Deal...watch this biotech space!
There have been so many fantastic posts here in the last week, CKD/DM isn’t the only thing in our pipeline, NASH is another big one. Our HIT Receptor technology also. The benefits are endless on drug discovery. It’s not uncommon to see new uses for drugs marketed previously also. I’m sure Dr B can vouch for this, I see it in clinical practice commonly.
@kates9999 I know you have been with us here for a while & welcomed too
@Pisces, you should never have to justify your investment, it’s pretty obvious why you have invested here, heart or not. I feel sorry your celebrity status on HC is a burden on you at times...we are happy to have you here, both of you, & to all new investors.
DXB has been a bit of a journey since I invested in July 17. 20:1 consolidation, CR. However Management run this company like clockwork & every box is ticked. I have every faith and always have. Really lovely you emailed Kathy with appreciation BT, might just do the same.
